KRAS proteins are known for their intrinsic GTPase activity and are “the most mutated protein in cancer”.1KRAS mutation is foundational to in vivo oncogenic transformation2,3 and is widely associated with pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), cholangiocarcinoma, and uterine endometrial carcinoma.1–3 Approximately 30% of all human cancers harbor RAS mutations, with KRAS mutations being prevalent. This evidence concerns the gene KRAS and cancer.